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Results were similar in the ITT population (HER2+ or HER2- patients). CONCLU-
SIONS: Utility values for patients with HER2+ MBC are generally similar for patients 
receiving letrozole plus lapatinib or letrozole plus placebo. Post-progression utility 
values were based largely on a single assessment for each patient and are may not be 
representative of patient utility during all post-progression survival.
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IMPACT OF AN INDIVIDUAL’S LOCUS OF CONTROL ON UTILITY 
VALUES FOR HEAD AND NECK CANCER HEALTH STATES
Levy AR1, Szabo S1, Johnston K1, Dobson RL1, Donato BM2
1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2Bristol-Myers Squibb Co, Wallingford, CT, 
USA
OBJECTIVES: The determinants of utilities for health are largely unknown. The 
psychosocial construct Locus of control (LOC) describes the extent to which individu-
als feel their health is determined by their actions, by a powerful external ﬁgure, or 
by chance. LOC is associated with health-related quality of life among cancer patients 
but its impact on utilities has not been examined. The objective was to estimate the 
effect of LOC on utilities for head and neck cancer (HNC) health states among 
Canadians without cancer. METHODS: A convenience sample of respondents without 
cancer was recruited according to the age- and sex-distribution of Canada in Vancou-
ver and Toronto. Standard gamble utilities were elicited for health states describing 
HNC stage and type. Standardized health state descriptions were based on literature 
review, trial data, and feedback from clinicians experienced in HNC treatment and 
quality-of-life researchers. Respondents completed the validated Multidimensional 
Health LOC scale. Mixed regression models were used to determine associations 
between interval locus of control scores and utilities, adjusting for demographic 
variables, HNC stage and type. RESULTS: Utility values were elicited from 101 
respondents with a mean age of 47 years (48% male). Mean utilities were: 0.62 for 
locoregional laryngeal, 0.61 for locoregional non-laryngeal, 0.57 for recurrent non-
laryngeal, 0.56 for recurrent laryngeal, 0.52 for metastatic non-laryngeal, 0.50 for 
metastatic laryngeal, and 0.34 for post-progression, HNC. There was suggestive evi-
dence that LOC was associated with utilities (P = 0.079). Respondents who had a 
dominant Chance LOC rated health states signiﬁcant lower (P = 0.012): for every one 
unit increase on the Chance subscale, there was a decrement of 0.011 in mean utility 
value. CONCLUSIONS: This evidence indicates that LOC is a determinant of utilities 
for head and neck cancer health states. Replicating these ﬁndings in other populations 
and diseases would shed insight into the psychosocial determinants of preferences.
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EVALUATION OF QUALITY OF LIFE FOR ANTI-CANCER TREATMENT 
AMONGST KOREAN METASTATIC BREAST CANCER PATIENTS: A 
MULTICENTER, CROSS-SECTIONAL STUDY
Lee JY1, Ko SK1, Kim EJ2
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OBJECTIVES: This research is designed to reveal Quality of life of Korean patients 
with metastatic breast cancer for cancer treatments. METHODS: This is a multicenter, 
cross-sectional study in breast cancer patients receiving palliative chemotherapy. Total 
199 patients with metastatic breast cancer were interviewed from 4 centers. Clinical, 
socio-demographic, and quality of life data were collected. Subjects completed a face-
to-face interview with trained interviewer to assess their health status for breast cancer 
treatment. Patients recalled the before diagnosis status under current situation. we 
used the three methods to evaluate the health status; EORTC QLQ-C30, BR-23, 
EQ-5D. RESULTS: Overall utility weights for EORTC QLQ C30 and EQ-5D was 
0.81 and 0.78 respectively(before diagnosis). It is higher than those of current 
(EORTC QLQ-C30: 0.54, EQ-5D: 0.60). the patients who are before diagnosis esti-
mated higher functioning score compared to current. (physical functioning scale; 
before cancer: 92.8, current 65.3) The higher the score is, the better patients’ function 
is. Symptom scale scores are the similar with functioning scale scores. The higher the 
score is, the worse the symptom is. before cancer status has lower symptom scale 
scores than current. (fatigue symptom scale; Before cancer: 25.2, current: 48.5) BR 
23 scale, there were deteriorations in patients for all domains compared to scores of 
before cancer patients. Especially, patient’ current body image score is signiﬁcantly 
lower than that of before diagnosis patients. (before diagnosis: 91.4, current: 46.4) 
CONCLUSIONS: There are few study of Quality of life in breast cancer patients. It 
is meaningful that this study provided the utility weights for breast cancer patients in 
Korea.
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PSYCHOMETRIC VALIDATION OF A PATIENT QUESTIONNAIRE 
EVALUATING SATISFACTION WITH A DARBEPOETIN ALPHA 
PRE-FILLED DEVICE FOR SELF-INJECTION 
(ARANESP®SURECLICKTMDEVICE), AND A HOME-SERVICE 
(2CARE®SERVICE) IN CHEMOTHERAPY-INDUCED ANAEMIC  
CANCER PATIENTS
de Jong FA1, Viala-Danten M2, van Herwaarden RH1, Poppe KA1, van Haaster CM1, 
Meunier J2, Rijnierse JJ1
1Amgen BV, Breda, The Netherlands, 2Mapi Values, Lyon, France
OBJECTIVES: To validate a questionnaire evaluating patient satisfaction with the 
darbepoetin alpha pre-ﬁlled device for self-injection (Aranesp®SureClickTMdevice) and 
the 2care®service for product delivery and helping patients with injection at home. 
METHODS: Patients with non-myeloid malignancies to be treated with 500mcg 
darbepoetin alfa three-weekly for chemotherapy-induced anaemia using the 
Aranesp®SureClickTMdevice and 2care®service were enrolled in a prospective, obser-
vational study in the The Netherlands. Following each of the ﬁrst three darbepoetin 
alpha-injections, patients completed a questionnaire speciﬁcally developed for this 
study. This questionnaire included items (answer ranges, 0–10) related to satisfaction 
with the device (5 items: ease-of-use/pain /anxiety/expectations/overall-satisfaction) 
and the 2care®service (9 items: quickness/delivery/punctuality/friendliness/compe-
tency/ﬂexibility/information/usefulness/overall-satisfaction). Questionnaire structure 
was deﬁned using factor analyses and conﬁrmed by multi-trait analysis. Internal 
consistency was evaluated by Cronbach’s alfa. Ranges of minimal important differ-
ences (MIDs) were calculated using anchor-based and distribution-based methods. 
Determinants of overall satisfaction with the Aranesp®SureClickTMdevice were ana-
lyzed by multiple regression analyses. RESULTS: A total of 283 patients were evalu-
able. At ﬁrst injection, median item-scores ranged from 8.0–9.4. Two composite scores 
were deﬁned (1 item not correlated with any scores: quickness 2care®-contact making 
appointment): satisfaction with the Aranesp®SureClickTMdevice and satisfaction with 
the 2care®service. Item-score correlations ranged from 0.61–0.81 and 0.64–0.79, 
respectively. Cronbach’s alfas were 0.85 and 0.84. All items met convergent and 
discriminant validity criteria. Plausible MIDs were 0.5–0.7 and 0.3 for satisfaction 
with the Aranesp®SureClickTMdevice and 2care®service, respectively. At ﬁrst injec-
tion, satisfaction with the Aranesp®SureClickTMdevice was mainly determined by 
expectations, pain, and ease-of-use. After 3 injections, the main driver was ease-of-use. 
CONCLUSIONS: Patients were satisﬁed with the Aranesp®SureClickTMdevice and 
2care®service. The satisfaction questionnaire showed good dimension structure and 
internal consistency reliability. MIDs were provided for interpretation of scores. 
Determinants of patient satisfaction were shown to change (ease-of-use becoming the 
main driver, while pain importance decreased) while the patient accumulates experi-
ence with the Aranesp®SureClickTMdevice.
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COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS 
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Basch E1, Reeve B2, Cleeland C3, Sloan J4, Mendoza T3, Abernethy A5, Bruner D6, Hay J1, 
Atkinson T1, Sit L1, Minasian L2, O’Mara A2, Burke L7, Schrag D8
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OBJECTIVES: The standard lexicon for reporting adverse events in NCI-sponsored 
trials is the Common Terminology Criteria for Adverse Events (CTCAE), which 
consists of over 800 individual items. Currently, all items are reported by clinicians. 
However, multiple studies have found that clinicians tend to underreport symptom 
severity and onset compared with patient self-reports. In October 2008, the NCI 
contracted a multi-institution consortium to develop patient versions of CTCAE items, 
and an administration electronic platform. METHODS: A multidisciplinary commit-
tee systematically identiﬁed CTCAE items with sufﬁcient subjective component to be 
amenable to patient reporting. Systematic reviews of publications and existing ques-
tionnaires, and analyses of existing data sets were conducted to determine optimal 
formats for questions and response options, and plain-language terms for each new 
“PRO-CTCAE” item. Cognitive interviews were conducted in 100 patients to reﬁne 
items. RESULTS: Seventy-seven “symptoms” were identiﬁed in the CTCAE which 
were amenable to patient reporting. The committee determined that measured attri-
butes for each symptom should include frequency, severity, and activity interference, 
assessed via discrete questions for each symptom. A standardized format for questions 
and response options, and plain language terms for each symptom were formulated. 
A web-based platform was developed for creating and administering the new PRO-
CTCAE items. CONCLUSIONS: A patient version of the CTCAE system, known as 
the PRO-CTCAE, has been developed. This prototype is undergoing further testing 
to assess its validity, reliability, usability, and feasibility for use in a variety of cancer 
care settings. The PRO-CTCAE system both will enhance adverse event reporting by 
directly integrating patient experiences and will foster consistency of data collection 
methods across studies.
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HOW MUCH DO PATIENTS WITH RENAL CELL CARCINOMA (RCC) 
VALUE PROGRESSION FREE SURVIVAL IN MEDICAL DECISION 
MAKING?—RESULTS FROM A BENEFIT-RISK CONJOINT STUDY
Hauber AB1, Mohamed AF1, Johnson FR1, Neary MP2
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BACKGROUND: Overall survival (OS) has been traditionally used as the primary 
endpoint in oncology trials, however cross-over to 2nd line agents may result in biases 
for OS. Recent trials have used progression free survival (PFS) as the primary endpoint. 
Understanding patient preferences regarding expected PFS vs. avoidance of risk for 
toxicities in medical decision-making is needed. OBJECTIVES: To estimate RCC 
patients’ willingness to accept toxicities and medication-related risks to increase PFS. 
METHODS: US residents aged 18 years and over with RCC completed a web-enabled, 
choice-format conjoint survey that presented a series of 12 trade-off questions, each 
including a pair of hypothetical RCC medication proﬁles. Each proﬁle was deﬁned by 
efﬁcacy (PFS), tolerability effects (fatigue, diarrhea, hand-foot syndrome, mouth 
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sores), and medication-related risks (liver failure, blood clot). OS was held constant 
at 32 months. Trade-off questions were based on predetermined experimental design 
with known statistical properties. Random-parameters logit model was used to esti-
mate a preference weight for each attribute level. Preference weights were used to 
calculate maximum levels of risks patients were willing to accept for increases in PFS. 
RESULTS: A total of 138 US subjects completed the survey. PFS was the most impor-
tant attribute to patients over the range of levels included in the survey, while remain-
ing attributes were ranked in order of importance as: fatigue, diarrhea, liver failure, 
hand-foot syndrome, blood clot, mouth sores. Increasing PFS by 10 months was as 
important as avoiding severe fatigue and 2-times as important as avoiding severe 
mouth sores. Patients were willing to accept blood-clot risks up to 5.5% (95% CI: 
3.6%–8.6%) and liver-failure risks up to 3.6% (95% CI: 2.6%–4.8%) to increase PFS 
by 10 months. CONCLUSIONS: PFS is a clinical outcome that is important to RCC 
patients. Patients were willing to accept higher treatment-related risks to increase PFS.
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PRO LABELLING CLAIMS IN ANTINEOPLASTIC AGENTS
Caron M, Emery MP
MAPI Research Trust, Lyon, France
OBJECTIVES: To review PRO labelling claims achieved in antineoplastic products in 
Europe and in the US. METHODS: PROLabels database was searched with neoplasm 
and oncology as keywords to identify antineoplastic agents with PRO labeling claims 
approved or revised in Europe since 1995 and in the US since 1998. FDA and EMEA 
websites and guidances were reviewed. Anti-emetic and analgesic products were not 
included. RESULTS: Among the 101 antineoplastic products approved, 18 were 
identiﬁed with PRO claims—10 in the U.S, 8 in Europe (including one in both agen-
cies)—for 11 different indications: non-small cell lung carcinoma, prostatic neoplasms, 
small cell lung carcinoma, Kaposi sarcoma, chronic myeloid leukemia, astrocytoma, 
pleural malignant mesothelioma, breast neoplasms, head & neck neoplasms, stomach 
neoplasms and colorectal neoplasms. Survival was primary endpoint for 12 products. 
Other primary endpoints included time to progression, response rate and response 
duration. PROs included in labels were primary endpoints in only two cases: one 
product used in prostatic neoplasms (improvement in pain) and one product approved 
for pancreatic neoplasms (clinical beneﬁt response including pain intensity, use of 
rescue medication and performance status). Both products were approved by the FDA. 
Health-related quality of life was clearly mentioned in the label of 7 products (4 
approved by the EMEA including 2 approved after the publication of the EMEA and 
FDA guidances, and 3 by the FDA, all approved before the publication of the guid-
ances). Of these 7 products, 3 approved by the EMEA and 1 by the FDA had an 
indication for non-small cell lung carcinoma. CONCLUSIONS: PROs are rarely used 
as primary endpoints in approval of antineoplastic agents except for assessing pallia-
tive response. When assessed, health-related quality of life is used as a supportive 
endpoint, and more often associated with non-small cell lung carcinoma, especially in 
Europe.
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LITERATURE REVIEW AND PRODUCT LABEL CLAIM REVIEW FOR THE 
DEVELOPMENT OF A PATIENT-REPORTED OUTCOME RESEARCH 
STRATEGY FOR CANCER-RELATED ANEMIA
Hackshaw MD, Brown J
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: An appraisal of patient-reported outcome (PRO) endpoints and exist-
ing instruments to measure such endpoints was conducted to identify and critically 
review potentially relevant and appropriate instruments for use in clinical trials of 
cancer-related anemia (CRA). The purpose of the study was to determine what PRO 
endpoints and instruments have been used to assess the impact of treatment in reduc-
ing CRA symptoms, and whether the instruments identiﬁed were likely to be of the 
standard acceptable by regulatory authorities to support a label claim. METHODS: 
A systematic search and review of 1486 published scientiﬁc abstracts was conducted 
using MEDLINE and EMBASE, as well as the supporting statements in regulatory 
agency labels for drugs used in the treatment of anemia. Consistency of the identiﬁed 
PRO measures and their psychometric properties with the current Food and Drug 
Administration (FDA) draft guidance on PROs supporting a labeling claim was also 
evaluated. RESULTS: A total of 29 instruments were identiﬁed. Four instruments were 
found to support a label claim or used speciﬁcally in the CRA population (FACT-F, 
FACT-An, CLAS/LASA, EORTC QLQ-C30); these were assessed further. Twenty-ﬁve 
were excluded from further assessment because they were speciﬁc to a particular 
disease other than cancer and covered aspects speciﬁc to these diseases which were 
not relevant to the CRA population. Other exclusion reasons included measurement 
of general health or health-related quality of life (HRQOL) and other symptoms that 
were neither speciﬁc to cancer nor anemia. CONCLUSIONS: None of the four instru-
ments assessed were found to meet all the criteria in the FDA draft guidance; however, 
the ﬁndings help inform the design of new PRO instruments for CRA.
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HEALTH RELATED QUALITY OF LIFE, FEAR OF RECURRENCE, IMPACT 
OF EVENTS, ILLNESS INTRUSIVENESS AND PSYHOLOGICAL DISTRESS 
IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
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OBJECTIVES: The purpose of this study was to explore differences among Veterans 
and private-patients on health related quality of life (HRQOL), fear of recurrence 
(FOR), impact of events (IE), illness intrusiveness (IITF) and psychological distress in 
non-muscle invasive bladder cancer (NMIBC) patients and provide direction for 
further study. METHODS: Cross sectional study design was used. Participants were 
drawn from a large private hospital (N = 38) and Veterans Affairs hospital (N = 29) 
in the southeast United States. HRQOL was measured with EORTC-QLQ-C30. FOR 
was measured with 5-item measure used in the Cancer of the Prostate Strategic 
Research Endeavor study. The IE Scale measures subjective response to stress and 
consists of two subscales, intrusive thoughts and avoidance. The IITF measure assesses 
impact of illness on functioning and consists of three subscales, intimacy, instrumental 
life and relationship-personal development. Psychological distress was measured with 
the Brief Symptom Index (BSI), an 18-item measure. Differences among Veterans vs. 
private-patients were assessed with student t-test or chi-square as appropriate. Analy-
ses were performed using the SAS v9.1.3. RESULTS: Majority of respondents were 
older (mean age at diagnosis 65.4(± 8.8) years), white (91.1%), males (83.6%), 
married (70.2%) and largest percentage (35.8%) reported getting some college educa-
tion. Veterans group did not differ from private-patients on age, education, ethnicity, 
relationship status, number of bladder cancer treatments received or time since diag-
nosis (years) (p > 0.05), but differed signiﬁcantly on gender (p = 0.0016). Number of 
comorbidities were also higher in the Veterans group (p = 0.0214). Veterans indicated 
signiﬁcantly higher FOR, psychological distress, illness intrusiveness on intimacy and 
instrumental life, and lower HRQOL compared to private-patients (p < 0.05). CON-
CLUSIONS: Veterans had higher level of FOR and psychological distress but lower 
HRQOL, than private-patients. Interventions to manage patients’ fear of recurrence, 
psychological distress and help them adapt to altered routine may assist NMIBC 
patients.
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EXPLORING THE BURDEN OF ILLNESS ON NEWLY DIAGNOSED 
ESOPHAGEAL CANCER PATIENTS IN TAIWAN –PRELIMINARY 
ANALYSIS
Lin HW, Ku CH, Lee RF, Shih TP, Liu YY, Lin CY
China Medical University, Taichung, Taiwan
OBJECTIVES: Esophageal cancer (EC) is the seventh cancer among male patients in 
Taiwan. Difﬁculty swallowing makes EC patients vulnerable to nutritional challenges 
and impacts their treatment outcomes and well-being. The aims of this study are to 
explore the EC patients’ burden of illness on nutritional and well-being aspects. 
METHODS: A longitudinal observation study is conducting to recruit newly diag-
nosed EC patients from the CMU Hospital in Taichung, Taiwan since June 2009. 
Fresh EC patients were assessed before (T0) and after receiving any main treatments 
(T1 [1-month], T2 [3-month], T3 [6-month] after treatment(s)) if it is not impossible. 
Well trained interviewers solicited patients’ responses on 1) Nutritional Risk Screen 
(NRS-2002); 2) Chinese versions of EQ-5D and FACT-E. The descriptive analyses 
were performed to examine the trends among different stages of EC patients. 
RESULTS: Up to the date of analysis(December 31, 2009), of 27 recruited EC patients, 
average age was 53 ± 9 years-old and more than 90% were diagnosed with squamous 
cell carcinoma (³85% with clinical stage at III and above). There were 23, 14, 5 and 
2 patients completed the T0, T1, T2 and T3 assessments, respectively. Approximately 
70% and 80% of patients at T0 and T2 had NR-2002S scored greater than 3 (with 
deﬁned risk of malnutrition). From T0 to T3, upon the solicited, completed responses, 
patients seemed to be deteriorated on the daily activities and social well-being (i.e., 
self-care, usual activity of EQ-5D, and physical and social well-being of FACT-E) but 
improve on esophageal cancer related symptoms and signs (additional concerns of EC) 
after treatments. CONCLUSIONS: This preliminary analysis showed the extent of EC 
patients’ burden of illness and its change over time. Further assessments are necessary 
to facilitate the decision making about appropriate management of EC patients on the 
aspect of nutrition and health-related quality of life.
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HEAD-TO-HEAD COMPARISONS OF QUALITY OF LIFE INSTRUMENTS 
FOR YOUNG ADULT SURVIVORS OF CHILDHOOD AND ADOLESCENT 
CANCER
Huang IC1, Quinn G2, Shenkman E1, Shearer P1
1University of Florida, Gainesville, FL, USA, 2H. Lee Mofﬁtt Cancer Center and Research 
Institute, Tampa, FL, USA
OBJECTIVES: Although several health-related quality of life (HRQOL) instruments 
exist for adult cancer survivors, little attention has been paid to identify appropriate 
instruments for young adult survivors of childhood and adolescent cancer (YASCAC). 
We aim to make head-to-head comparisons of 3 HRQOL instruments for YASCAC. 
METHODS: We collected data via telephone interviews between 05/01/2009 and 
09/30/2009 from 141 YASCAC who were off therapy at least 2 years without cancer 
and enrolled in the CSP and/or the UF Tumor Registry. Each subject reported his/her 
late effects (yes/no) and HRQOL. HRQOL was measured using the Quality of Life 
